{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:08:28Z","timestamp":1791925708664,"version":"4.3.4"},"reference-count":113,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:00:00Z","timestamp":1591920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"DOI":"10.3389\/fnins.2020.00609","type":"journal-article","created":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:41:05Z","timestamp":1591922465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":89,"title":["Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders"],"prefix":"10.3389","volume":"14","author":[{"given":"Emma M.","family":"O\u2019Connell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk W.","family":"Lohoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001043","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke.","volume":"2","author":"Abboud","year":"2007","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00120","article-title":"Proprotein convertase subtilisin\/kexin type 9, brain cholesterol homeostasis and potential implication for Alzheimer\u2019s disease.","volume":"11","author":"Adorni","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104707","article-title":"Insulin signaling pathway and related molecules: role in neurodegeneration and Alzheimer\u2019s disease.","volume":"135","author":"Akhtar","year":"2020","journal-title":"Neurochem. Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/ijnp\/pyy060","article-title":"Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study.","volume":"21","author":"Alghamdi","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1042\/CS20100094","article-title":"The vascular contribution to Alzheimer\u2019s disease.","volume":"119","author":"Altman","year":"2010","journal-title":"Clin. Sci."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/srep17559","article-title":"Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics.","volume":"5","author":"An","year":"2015","journal-title":"Sci. Rep."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010838","article-title":"Pretreatment with PCSK9 Inhibitor protects the brain against cardiac ischemia\/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation.","volume":"8","author":"Apaijai","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/srep18224","article-title":"The influence of OLR1 and PCSK9 gene polymorphisms on ischemic stroke: evidence from a meta-analysis.","volume":"5","author":"Au","year":"2015","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.cub.2006.10.029","article-title":"ApoE receptor 2 controls neuronal survival in the adult brain.","volume":"16","author":"Beffert","year":"2006","journal-title":"Curr. Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (Ldl) receptor and Ldl cholesterol.","volume":"279","author":"Benjannet","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1648","article-title":"Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer\u2019s disease and Parkinson\u2019s disease: mendelian randomisation study.","volume":"357","author":"Benn","year":"2017","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.11.002","article-title":"Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study.","volume":"21","author":"Bettermann","year":"2012","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/jech.2009.100826","article-title":"Statins and serum cholesterol\u2019s associations with incident dementia and mild cognitive impairment.","volume":"65","author":"Beydoun","year":"2011","journal-title":"J. Epidemiol. Community Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/cyto.a.20346","article-title":"Proapoptotic effects of NARC 1 (= PCSK9), the gene encoding a novel serine proteinase.","volume":"69","author":"Bingham","year":"2006","journal-title":"Cytometry A"},{"key":"B16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.mam.2009.02.001","article-title":"Oxysterols and neurodegenerative diseases.","volume":"30","author":"Bj\u00f6rkhem","year":"2009","journal-title":"Mol. Aspects Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.jacc.2020.01.033","article-title":"High-density lipoproteins are the main carriers of PCSK9 in the circulation.","volume":"75","author":"Burnap","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064145","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).","volume":"8","author":"Canuel","year":"2013","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.06.336","article-title":"PCSK9 cerebrospinal fluid concentrations are not increased in Alzheimer\u2019s disease.","volume":"263","author":"Cariou","year":"2017","journal-title":"Atherosclerosis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2016.09.023","article-title":"PCSK9 inhibitors: A new era in stroke prevention?","volume":"37","author":"Castilla-Guerra","year":"2017","journal-title":"Eur. J. Intern. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy.","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11745-014-3895-6","article-title":"PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.","volume":"49","author":"Chen","year":"2014","journal-title":"Lipids"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1073\/pnas.051630598","article-title":"An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis.","volume":"98","author":"Chiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00441","article-title":"Variability in total cholesterol concentration is associated with the risk of dementia: a nationwide population-based cohort study.","volume":"10","author":"Chung","year":"2019","journal-title":"Front. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, Low LDL, and protection against coronary heart disease.","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice.","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov. Disord."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3233\/JAD-170993","article-title":"PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer\u2019s disease.","volume":"62","author":"Courtemanche","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/eurheartj\/ehy357","article-title":"PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor.","volume":"40","author":"Da Dalt","year":"2018","journal-title":"Eur. Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2016.03.024","article-title":"Cholesterol-lowering interventions and stroke: insights from IMPROVE-IT.","volume":"248","author":"De Caterina","year":"2016","journal-title":"Atherosclerosis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1515\/BC.2010.129","article-title":"Lipoprotein receptors\u2013an evolutionarily ancient multifunctional receptor family.","volume":"391","author":"Dieckmann","year":"2010","journal-title":"Biol. Chem."},{"key":"B31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1515\/BC.2009.035","article-title":"Central nervous system: cholesterol turnover, brain development and neurodegeneration.","volume":"390","author":"Dietschy","year":"2009","journal-title":"Biol. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","article-title":"PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages.","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.trsl.2015.10.004","article-title":"Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.","volume":"173","author":"Ferri","year":"","journal-title":"Transl. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement.","volume":"253","author":"Ferri","year":"","journal-title":"Atherosclerosis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels.","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9.","volume":"376","author":"Fitzgerald","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbalip.2017.05.002","article-title":"APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.","volume":"1862","author":"Fu","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"B38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/1715163515578692","article-title":"Statins and their effect on cognition: let\u2019s clear up the confusion.","volume":"148","author":"Gauthier","year":"2015","journal-title":"Can. Pharm. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab.","volume":"377","author":"Giugliano","year":"","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/clc.22678","article-title":"Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.","volume":"40","author":"Giugliano","year":"","journal-title":"Clin. Cardiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1194\/jlr.M800027-JLR200","article-title":"Plasma PCSK9 preferentially reduces liver LDL receptors in mice.","volume":"49","author":"Grefhorst","year":"2008","journal-title":"J. Lipid Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.12659\/MSM.892091","article-title":"Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.","volume":"20","author":"Han","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.4103\/1673-5374.213552","article-title":"Association and differences in genetic polymorphisms in PCSK9 gene in subjects with lacunar infarction in the Han and Uygur populations of Xinjiang Uygur Autonomous Region of China.","volume":"12","author":"Han","year":"2017","journal-title":"Neural Regen. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","article-title":"Microglial dysfunction and defective \u03b2-amyloid clearance pathways in aging Alzheimer\u2019s disease mice.","volume":"28","author":"Hickman","year":"2008","journal-title":"J. Neurosci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1471-4159.2004.03007.x","article-title":"Multiple pathways of apolipoprotein E signaling in primary neurons.","volume":"93","author":"Hoe","year":"2005","journal-title":"J. Neurochem."},{"key":"B46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"B47","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/eurheartj\/ehx373","article-title":"Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.","volume":"39","author":"Hopewell","year":"2017","journal-title":"Eur. Heart J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/embor.2008.132","article-title":"PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.","volume":"9","author":"Jonas","year":"2008","journal-title":"EMBO Rep."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.116.001632","article-title":"PCSK9 loss-of-function variants, low-density lipoprotein cholesterol, and risk of coronary heart disease and stroke: data from 9 studies of blacks and whites.","volume":"10","author":"Kent","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/STROKEAHA.108.539643","article-title":"Low Level of low-density lipoprotein cholesterol increases hemorrhagic transformation in large artery atherothrombosis but not in cardioembolism.","volume":"40","author":"Kim","year":"2009","journal-title":"Stroke"},{"key":"B51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial.","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"B52","doi-asserted-by":"publisher","first-page":"8279","DOI":"10.1074\/jbc.M112.421370","article-title":"Low density lipoprotein binds to proprotein convertase subtilisin\/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.","volume":"288","author":"Kosenko","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6030063","article-title":"Inclisiran: a new promising agent in the management of hypercholesterolemia.","volume":"6","author":"Kosmas","year":"2018","journal-title":"Diseases"},{"key":"B54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2008.02.003","article-title":"Effect of protein convertase subtilisin\/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population.","volume":"94","author":"Kostrzewa","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"B55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nature05901","article-title":"Transvascular delivery of small interfering RNA to the central nervous system.","volume":"448","author":"Kumar","year":"2007","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1021\/acsnano.6b03858","article-title":"Neuron-targeted nanoparticle for siRNA delivery to traumatic brain injuries.","volume":"10","author":"Kwon","year":"2016","journal-title":"ACS Nano"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","article-title":"PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling.","volume":"69","author":"Kysenius","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53603-6","article-title":"PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.","volume":"9","author":"Lee","year":"","journal-title":"Sci. Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/acer.14039","article-title":"PCSK9 is increased in cerebrospinal fluid of individuals with alcohol use disorder.","volume":"43","author":"Lee","year":"","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1194\/jlr.M006635","article-title":"PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain.","volume":"51","author":"Liu","year":"2010","journal-title":"J. Lipid Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH.","volume":"12","author":"Lo Surdo","year":"2011","journal-title":"EMBO Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/mp.2017.168","article-title":"Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder.","volume":"23","author":"Lohoff","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0304-3940(02)00942-4","article-title":"Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer\u2019s disease.","volume":"332","author":"Ma","year":"2002","journal-title":"Neurosci. Lett."},{"key":"B65","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/2047487319831500","article-title":"Changes in circulating pro-protein convertase subtilisin\/kexin type 9 levels \u2013 experimental and clinical approaches with lipid-lowering agents.","volume":"26","author":"Macchi","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacl.2018.05.012","article-title":"PCSK9 and neurocognitive function: should it be still an issue after FOURIER and EBBINGHAUS results?","volume":"12","author":"Mannarino","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1194\/jlr.M300203-JLR200","article-title":"Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice.","volume":"44","author":"Maxwell","year":"2003","journal-title":"J. Lipid Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCULATIONAHA.117.029785","article-title":"PCSK9 variants, low-density lipoprotein cholesterol, and neurocognitive impairment.","volume":"137","author":"Mefford","year":"2018","journal-title":"Circulation"},{"key":"B69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejim.2016.06.023","article-title":"Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: effect on stroke risk.","volume":"34","author":"Milionis","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.118.002196","article-title":"Genetic assessment of potential long-term on-target side effects of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibitors.","volume":"12","author":"Nelson","year":"2019","journal-title":"Circ. Genom. Precis. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1471-4159.2009.05917.x","article-title":"Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats.","volume":"109","author":"Nieweg","year":"2009","journal-title":"J. Neurochem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/13543784.2018.1442435","article-title":"Inclisiran for the treatment of dyslipidemia.","volume":"27","author":"Nishikido","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B73","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials.","volume":"30","author":"Ott","year":"2015","journal-title":"J. Gen. Intern. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0891988718764330","article-title":"Loss-of-function PCSK9 mutations are not associated with Alzheimer disease.","volume":"31","author":"Paquette","year":"2018","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.biomaterials.2014.10.068","article-title":"Enhanced BBB permeability of osmotically active poly(mannitol-co-PEI) modified with rabies virus glycoprotein via selective stimulation of caveolar endocytosis for RNAi therapeutics in Alzheimer\u2019s disease.","volume":"38","author":"Park","year":"2015","journal-title":"Biomaterials"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.6.625","article-title":"Changes in memory function and neuronal activation associated with atorvastatin therapy.","volume":"30","author":"Parker","year":"2010","journal-title":"Pharmacotherapy"},{"key":"B77","first-page":"2787","article-title":"PCSK9 regulates apoptosis in human neuroglioma u251 cells via mitochondrial signaling pathways.","volume":"8","author":"Piao","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220254","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in Alzheimer\u2019s disease: a genetic and proteomic multi-cohort study.","volume":"14","author":"Picard","year":"2019","journal-title":"PLoS One"},{"key":"B79","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1212\/WNL.0000000000001202","article-title":"Lipid and lipoprotein measurements and the risk of ischemic vascular events.","volume":"84","author":"Pikula","year":"2015","journal-title":"Neurology"},{"key":"B80","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.","volume":"283","author":"Poirier","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1471-4159.2006.03928.x","article-title":"Implication of the proprotein convertase NARC-1\/PCSK9 in the development of the nervous system.","volume":"98","author":"Poirier","year":"2006","journal-title":"J. Neurochem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1194\/jlr.P033969","article-title":"PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population.","volume":"54","author":"Postmus","year":"2013","journal-title":"J. Lipid Res."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.118.002162","article-title":"Large-scale phenome-wide association study of PCSK9 variants demonstrates protection against ischemic stroke.","volume":"11","author":"Rao","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaneurol.2013.5390","article-title":"Associations between serum cholesterol levels and cerebral amyloidosis.","volume":"71","author":"Reed","year":"2014","journal-title":"JAMA Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/hmg\/ddq079","article-title":"Analysis of lipid pathway genes indicates association of sequence variation near SREBF1\/TOM1L2\/ATPAF2 with dementia risk.","volume":"19","author":"Reynolds","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials.","volume":"69","author":"Robinson","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1194\/jlr.M014118","article-title":"PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.","volume":"52","author":"Rousselet","year":"2011","journal-title":"J. Lipid Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-019-0078-7","article-title":"A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR.","volume":"4","author":"Safarova","year":"2019","journal-title":"NPJ Genom. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.biocel.2008.01.030","article-title":"The activation and physiological functions of the proprotein convertases.","volume":"40","author":"Seidah","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases.","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials.","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ. Res."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1097\/00041444-200512000-00004","article-title":"No genetic association between PCSK9 polymorphisms and Alzheimer\u2019s disease and plasma cholesterol level in Japanese patients.","volume":"15","author":"Shibata","year":"2005","journal-title":"Psychiatr. Genet."},{"key":"B100","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12031-014-0238-2","article-title":"Effect of E670G polymorphism in PCSK9 gene on the risk and severity of coronary heart disease and ischemic stroke in a Tunisian cohort.","volume":"53","author":"Slimani","year":"2014","journal-title":"J. Mol. Neurosci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1172\/JCI81108","article-title":"Endothelial LRP1 transports amyloid-\u03b2(1-42) across the blood-brain barrier.","volume":"126","author":"Storck","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B102","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","article-title":"PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials.","volume":"38","author":"Swiger","year":"2015","journal-title":"Drug Saf."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.jacc.2018.06.043","article-title":"Effect of long-term low lipoproteins on neurocognitive function.","volume":"72","author":"Verbeek","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B105","first-page":"5076","article-title":"Novel apoE receptor mimetics reduce LPS-induced microglial inflammation.","volume":"11","author":"Wang","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1161\/STROKEAHA.113.001326","article-title":"Cholesterol levels and risk of hemorrhagic stroke.","volume":"44","author":"Wang","year":"2013","journal-title":"Stroke"},{"key":"B107","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/jamaneurol.2019.0648","article-title":"Association of early-onset alzheimer disease with elevated low-density lipoprotein cholesterol levels and rare genetic coding variants of APOB.","volume":"76","author":"Wingo","year":"2019","journal-title":"JAMA Neurol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2009.08.015","article-title":"Higher incidence of mild cognitive impairment in familial hypercholesterolemia.","volume":"123","author":"Zamb\u00f3n","year":"2010","journal-title":"Am. J. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3349\/ymj.2019.60.7.659","article-title":"Associations for BCO2, PCSK9, and TR1B1 polymorphism and lifestyle factors with ischemic stroke: a nested case-control study.","volume":"60","author":"Zhao","year":"2019","journal-title":"Yonsei Med. J."},{"key":"B111","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.","volume":"79","author":"Zhao","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"B112","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.tibtech.2018.01.006","article-title":"Nanotechnology-based strategies for siRNA brain delivery for disease therapy.","volume":"36","author":"Zheng","year":"2018","journal-title":"Trends Biotechnol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JAD-160411","article-title":"Increased pcsk9 cerebrospinal fluid concentrations in Alzheimer\u2019s disease.","volume":"55","author":"Zimetti","year":"2017","journal-title":"J. Alzheimers Dis."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00609\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,12]],"date-time":"2020-06-12T00:41:09Z","timestamp":1591922469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00609\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,12]]},"references-count":113,"alternative-id":["10.3389\/fnins.2020.00609"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2020.00609","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,12]]},"article-number":"609"}}